KBio, Inc

KBio is a biofoundry ecosystem that applies plant-based manufacturing to therapeutics, bioingredients, and bioactives. The company describes its RP3 (“Rapid Protein Production”) platform as a plant-based protein production platform that integrates a plant-based protein manufacturing system, innovative technologies, and strategic global partnerships to enable rapid protein production “quickly and at scale,” supporting the development of plant-based products for health applications [1][7]. KBio’s stated focus areas include antibody therapies for areas of high unmet need and pandemic preparedness and response, using its plant-based production system to create antibodies and vaccines on shorter timeframes than industry norms [2].

KBio positions its plant-powered approach as a way to make therapeutics and other biologics feasible in a more sustainable and scalable manner, emphasizing speed of drug-candidate creation and scalability via plant-based manufacturing [1][2]. The company also highlights partnership efforts that leverage BAT’s plant-based technological capabilities to optimize RP3, and mentions strategic relationships intended to extend R&D reach and capabilities across the UK, US, and EU [6].